Background
Monoclonal gammopathy of undetermined significance (MGUS) progresses to multiple myeloma or a related disorder at ~1% per year, but tools to risk-stratify individual patients were limited. This Mayo Clinic study used a long-term cohort of MGUS patients with stored serum to derive a simple prognostic model for progression.
Interventions and follow up
Design: Retrospective cohort of 1,148 MGUS patients (diagnosed 1960-1994) with cryopreserved serum, observed for progression.
Risk model factors: (1) serum M-spike ≥1.5 g/dL; (2) non-IgG isotype; (3) abnormal serum free light chain (FLC) ratio (outside 0.26-1.65).
Primary endpoint: Progression to multiple myeloma, AL amyloidosis, lymphoma, or related malignancy.
mFollow up: Median 15.4 years.
Risk model factors: (1) serum M-spike ≥1.5 g/dL; (2) non-IgG isotype; (3) abnormal serum free light chain (FLC) ratio (outside 0.26-1.65).
Primary endpoint: Progression to multiple myeloma, AL amyloidosis, lymphoma, or related malignancy.
mFollow up: Median 15.4 years.
Results
Progression: 87/1148 (7.6%) progressed — multiple myeloma (n=53), IgM lymphoma (n=17), AL amyloidosis (n=6), macroglobulinemia (n=6), CLL (n=3), plasmacytoma (n=2).
Independent predictors: abnormal FLC ratio, non-IgG isotype, and M-protein ≥1.5 g/dL each independently predicted progression.
Low-risk (0 factors): 20-yr risk ~5%.
Low-intermediate (1 factor): 20-yr risk ~21%.
High-intermediate (2 factors): 20-yr risk ~37%.
High-risk (3 factors): 20-yr risk ~58%.
Note: 20-yr absolute risk accounts for death as a competing risk.
Independent predictors: abnormal FLC ratio, non-IgG isotype, and M-protein ≥1.5 g/dL each independently predicted progression.
Low-risk (0 factors): 20-yr risk ~5%.
Low-intermediate (1 factor): 20-yr risk ~21%.
High-intermediate (2 factors): 20-yr risk ~37%.
High-risk (3 factors): 20-yr risk ~58%.
Note: 20-yr absolute risk accounts for death as a competing risk.
Adverse events
Safety: Not applicable — this was an observational risk-stratification analysis with no therapeutic intervention.
Toxicity: No treatment-related adverse events were assessed.
Toxicity: No treatment-related adverse events were assessed.
Conclusions
Three readily measurable factors (M-protein ≥1.5 g/dL, non-IgG isotype, abnormal FLC ratio) stratify MGUS into low, low-intermediate, high-intermediate, and high-risk groups for progression, informing surveillance frequency and patient counseling.
Key Limitations
Retrospective single-institution cohort with serum from an older diagnostic era; FLC assays were applied to stored samples. The model predicts population-level risk and does not capture all biologic heterogeneity (e.g., cytogenetics, marrow plasma-cell percentage).
Clinical Context
This Mayo model underpins risk-adapted MGUS monitoring endorsed by IMWG and ASCO/ESMO guidance: low-risk MGUS may not require routine bone marrow biopsy or imaging at diagnosis, whereas higher-risk patients warrant closer surveillance. It remains a foundational reference for counseling and follow-up intervals.